C7A refers to Malignant neuroendocrine tumors, a category of cancers arising from hormone-producing neuroendocrine cells, either as primary (C7A) or metastatic/secondary (C7B) tumors. These tumors can be found in the gastrointestinal tract, pancreas, lungs, and other areas, and may secrete hormones causing systemic symptoms.
Symptoms
- Flushing and skin redness – Due to hormone secretion
- Diarrhea – A common symptom of carcinoid syndrome
- Abdominal pain – From tumor growth or obstruction
- Wheezing or shortness of breath – In pulmonary neuroendocrine tumors
- Palpitations – Related to hormonal surges
- Weight loss – Seen in systemic or metastatic disease
- Fatigue – Often a result of tumor burden or hormone effects
Diagnosis
Diagnosis of Malignant neuroendocrine tumors includes blood and urine tests (e.g., chromogranin A, 5-HIAA), imaging (CT, MRI, Octreoscan, PET), and biopsy. Histological grading and immunohistochemistry help determine tumor type, grade, and hormone activity. Accurate classification informs the treatment approach.
ICD10 Code Usage
ICD10 code C7A is used in oncology and endocrinology to document primary and secondary neuroendocrine tumors in electronic health records, cancer registries, and insurance billing. It supports tumor tracking, response evaluation, and care coordination.
Related Codes
FAQs
Q1: What is ICD10 code C7A?
A: This code refers to Malignant neuroendocrine tumors, used to classify hormone-secreting neuroendocrine tumors.
Q2: What are neuroendocrine tumors?
A: These are rare cancers arising from cells that release hormones into the blood in response to nerve signals.
Q3: Are these tumors treatable?
A: Yes, treatments include surgery, hormone therapy, somatostatin analogs, and targeted drugs.
Q4: What is the difference between C7A and C7B?
A: C7A refers to primary neuroendocrine tumors; C7B refers to metastatic or secondary forms.
Q5: Can these tumors spread?
A: Yes, especially to the liver, lymph nodes, and bone, requiring systemic therapy.
Conclusion
ICD10 code C7A is essential for diagnosing and managing Malignant neuroendocrine tumors. It facilitates treatment planning, hormone monitoring, and cancer tracking. Proper use supports comprehensive care, accurate documentation, and improved outcomes for patients with neuroendocrine tumors.
Ready to Transform Your Documentation?
Get started for $0 – no credit card needed. You'll get up to 20 sessions free.
Start Free Trial